Factors associated with the use of corticosteroids in the initial management of idiopathic pulmonary fibrosis

Pharmacoepidemiology and Drug Safety

Volumn 19, Issue 7, 2010, Pages 756-762

  Munson, Jeffrey C ^a,b   Kreider, Maryl ^a   Chen, Zhen ^c   Christie, Jason D ^a,b   Kimmel, Stephen E ^a,b  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Adverse events; Corticosteroids; Drug therapy; Idiopathic pulmonary fibrosis; Prescribing

Indexed keywords

CORTICOSTEROID DERIVATIVE; OXYGEN; GLUCOCORTICOID;

AGED; ARTICLE; CLINICAL FEATURE; COMORBIDITY; CONTROLLED STUDY; DATA BASE; DYSPNEA; FEMALE; HUMAN; IDIOPATHIC DISEASE; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT DURATION; ADULT; AGE; COHORT ANALYSIS; FACTUAL DATABASE; IDIOPATHIC PULMONARY FIBROSIS; MIDDLE AGED; OXYGEN THERAPY; PROCEDURES; REGRESSION ANALYSIS; SEX DIFFERENCE; UNITED KINGDOM; VERY ELDERLY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; COHORT STUDIES; DATABASES, FACTUAL; FEMALE; GLUCOCORTICOIDS; GREAT BRITAIN; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MALE; MIDDLE AGED; OXYGEN INHALATION THERAPY; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS;

EID: 77955637641     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1959     Document Type: Article

References (20)

1. Coultas DB, Zumwalt RE, Black WC, Sobonya RE. The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med 1994; 150(4): 967-972.
2. Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006; 174(7): 810-816.
3. Gribbin J, Hubbard RB, Le Jeune I, Smith CJ, West J, Tata LJ. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax 2006; 61(11): 980-985.
4. Flaherty KR, Toews GB, Lynch JP 3rd, et al. Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy, and survival. Am J Med 2001; 110(4): 278-282.
5. Gay SE, Kazerooni EA, Toews GB, et al. Idiopathic pulmonary fibrosis: predicting response to therapy and survival. Am J Respir Crit Care Med 1998; 157(4 Pt 1): 1063-1072.
6. Johnson MA, Kwan S, Snell NJ, Nunn AJ, Darbyshire JH, Turner-Warwick M. Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis. Thorax 1989; 44(4): 280-288.
7. Collard HR, Loyd JE, King TE Jr, Lancaster LH. Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians. Respiratory Med 2007; 101(9): 2011-2016.
8. Hubbard R, Venn A. The impact of coexisting connective tissue disease on survival in patients with fibrosing alveolitis. Rheumatology (Oxford). 2002; 41(6): 676-679.
9. Johnston ID, Prescott RJ, Chalmers JC, Rudd RM. British Thoracic Society study of cryptogenic fibrosing alveolitis: current presentation and initial management. Fibrosing Alveolitis Subcommittee of the Research Committee of the British Thoracic Society. Thorax 1997; 52(1): 38-44.
10. Rudd RM, Prescott RJ, Chalmers JC, Johnston ID. British thoracic society study on cryptogenic fibrosing alveolitis: response to treatment and survival. Thorax 2007; 62(1): 62-66.
11. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000; 161(2 Pt 1): 646-664.
12. Hubbard R, Lewis S, Smith C, et al. Use of nicotine replacement therapy and the risk of acute myocardial infarction, stroke, and death. Tob Control 2005; 14(6): 416-421.
13. Kell P, Hvidsten K, Morant S, Harnett J, Bridge S. Factors that predict changing the type of phosphodiesterase type 5 inhibitor medication among men in the UK. Br J Urol 2007; 99(4): 860-863.
14. Mortimer KJ, Tata LJ, Smith CJ, et al. Oral and inhaled corticosteroids and adrenal insufficiency: a case-control study. Thorax 2006; 61(5): 405-408.
15. Smeeth L, Cook C, Thomas S, Hall AJ, Hubbard R, Vallance P. Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting. Lancet 2006; 367(9516): 1075-1079.
16. Gribbin J, Hubbard R, Smith C. Role of diabetes mellitus and gastro-oesophageal reflux in the aetiology of idiopathic pulmonary fibrosis. Respir Med 2009; 103(6): 927-931.
17. Hubbard R, Venn A, Lewis S, Britton J. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am J Respir Crit Care Med 2000; 161(1): 5-8.
18. Lewis JD, Bilker WB, Weinstein RB, Strom BL. The relationship between time since registration and measured incidence rates in the General Practice Research Database. Pharmacoepidemiol Drug Saf 2005; 14(7): 443-451.
19. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986; 42(1): 121-130.
20. Wells AU, Hirani N. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 2008; 63(Suppl-V): v 1-58.